ArticleFrontiers in pharmacology2024
A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS).
Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Pharmacovigilance signal detection of rilonacept using FAERS with exploratory Mendelian randomization analysis.International journal of clinical pharmacy · 2026Article
- Peripheral nervous system safety signals of antibody-drug conjugates: cross-database reproducibility and labeling gaps identified using FAERS, JADER, and CVARD.Frontiers in pharmacology · 2026Article
- Systematic analysis and mechanistic investigation of cardiac adverse events associated with antibody-drug conjugates using FAERS database.International journal of surgery (London, England) · 2026Article
- Chemotherapy-induced peripheral neuropathy in breast cancer: a narrative review.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- A real-world study of adverse event profiles associated with the four key components of antibody-drug conjugates based on the FAERS database.Frontiers in pharmacology · 2026Article
- Chemotherapy-induced neuropathy in monomethyl Auristatin E treatment: prevention by lithium.British journal of cancer · 2025Article
- Real-World pharmacovigilance analysis of drug-related conjunctivitis using the FDA adverse event reporting system database.Scientific reports · 2025Article
- Rotigotine safety in real-world settings: a pharmacovigilance study using FAERS data.BMC pharmacology & toxicology · 2025Article
- A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod.Frontiers in pharmacology · 2025Article
- A pharmacovigilance study on probiotic preparations based on the FDA Adverse Event Reporting System from 2005 to 2023.Frontiers in cellular and infection microbiology · 2025Article
- A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib.Frontiers in pharmacology · 2024Article
- Early Neurotoxicity following a Single Dose of Brentuximab in a Patient with Epstein Bar Virus Driven Lymphoma: A Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.